Digest Network Come funziona
Network
/
Società
An
Non verificato

Anova Enterprises, Inc.

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieSaluteScienza

10 comunicati stampa

Guarda tutti i comunicati
21/07/2026
Tecnica
Scienza
Medicina - Varie
Software
Biotecnologia
Salute
Farmaceutica
Information Technology
Industria
Anova Expands Platform With Launch of Next-Generation eTMF Solution for Sponsors, CROs, and Research Sites
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
15/07/2026
Mercato del lavoro
Industria
Scienza
Tecnica
Medicina - Varie
Software
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
Anova and Nouveau Biosciences Announce Partnership to Deliver Clinical Trials of Kromastat for the Treatment of Relapsed or Refractory Cutaneous and Peripheral T-Cell Lymphoma
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
28/04/2026
Industria
Scienza
Software
Biotecnologia
Salute
Tecnica
Five Hundredth Urology Research Site Joins Anova’s Global Urology Research Network
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
12/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Anova Launches Free AI-enabled Clinical Trial Patient Matching Solution as Part of a Global Just-in-time Research Network
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
08/12/2025
Analisi di mercato
Industria
Information Technology
Biotecnologia
Tecnica
Salute
Farmaceutica
Scienza
Software
Medicina - Varie
Anova Today Announced the Enrollment of 550+ Patients at 50+ Sites in Six Months for a Single Study
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
23/09/2025
Industria
Scienza
Software
Farmaceutica
Salute
Information Technology
Tecnica
Medicina - Varie
Anova Launches Global Clinical Registry to Accelerate Research and Access to Promising New Treatments
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
05/03/2025
Industria
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
29/01/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Anova Expands Leadership Team to Manage Growth and Drive Innovation
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
01/05/2024
Accessori
Vetrine/Shopping
Formazione professionale
Scuola/Istruzione
Amministrazione Pubblica
Finanza
Risparmio/Affari personali
Fondi di investimento
Medicina - Varie
Software
Scienza
Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0
25/07/2023
Accessori
Vetrine/Shopping
Medicina - Varie
Scienza
United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma
Fonte
Anova Enterprises, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0